NCT02553837View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult

PHASE3UnknownINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

July 31, 2022

Conditions
Healthy
Interventions
BIOLOGICAL

Hantavax injection

A single 0.5mL dose intramuscular or subcutaneous injection

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY